Tonix Pharmaceuticals Holding Stock Annual Yield
| TNXP Stock | USD 0.20 0.02 11.11% |
Tonix Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Tonix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tonix Stock. The fundamental analysis module provides a way to measure Tonix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tonix Pharmaceuticals stock.
Tonix | Annual Yield |
Tonix Pharmaceuticals Holding Company Annual Yield Analysis
Tonix Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Tonix Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Tonix Pharmaceuticals is extremely important. It helps to project a fair market value of Tonix Stock properly, considering its historical fundamentals such as Annual Yield. Since Tonix Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tonix Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tonix Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Tonix Pharmaceuticals Holding has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Tonix Annual Yield Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tonix Pharmaceuticals' direct or indirect competition against its Annual Yield to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tonix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tonix Pharmaceuticals by comparing valuation metrics of similar companies.Tonix Pharmaceuticals is currently under evaluation in annual yield category among related companies.
Tonix Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (7.23) % | ||||
| Current Valuation | 73.36 K | ||||
| Shares Outstanding | 95.54 M | ||||
| Shares Owned By Institutions | 20.71 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 0.15 X | ||||
| Price To Sales | 2.00 X | ||||
| Revenue | 7.77 M | ||||
| EBITDA | (114.09 M) | ||||
| Net Income | (116.66 M) | ||||
| Cash And Equivalents | 145.48 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 9.81 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.05 X | ||||
| Book Value Per Share | 1.80 X | ||||
| Cash Flow From Operations | (102 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (6.85) X | ||||
| Target Price | 2.97 | ||||
| Number Of Employees | 103 | ||||
| Beta | 2.17 | ||||
| Market Capitalization | 18.84 M | ||||
| Total Asset | 154.46 M | ||||
| Retained Earnings | (600.66 M) | ||||
| Working Capital | 28.88 M | ||||
| Current Asset | 46.36 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 154.46 M |
About Tonix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tonix Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tonix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tonix Pharmaceuticals Piotroski F Score and Tonix Pharmaceuticals Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Tonix Stock analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Tonix Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tonix Pharmaceuticals. If investors know Tonix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tonix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.85) | Revenue Per Share 0.456 | Return On Assets (0.39) | Return On Equity (0.75) |
The market value of Tonix Pharmaceuticals is measured differently than its book value, which is the value of Tonix that is recorded on the company's balance sheet. Investors also form their own opinion of Tonix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tonix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tonix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tonix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tonix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tonix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tonix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.